Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label comparison of GZR18 versus semaglutide in adults with obesity or overweight
CTR20252970Phase 3Active
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bofanglutide, semaglutide in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by Gannex Pharma Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
bofanglutidesemaglutide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252970.